Introduction
Distal spinal muscular atrophy (DSMA) forms a heterogeneous group of rare neuromuscular disorders characterized by progressive anterior horn cell degeneration, leading to motor weakness and muscular atrophy predominating in the distal part of the limbs. Numerous DSMA phenotypes have been reported, differing by their mode of inheritance, age at onset and distribution of paralyses. 1 -3 We have previously reported the clinical profile of chronic distal spinal atrophy (Chronic DSMA) with autosomal recessive inheritance in a large inbred family from Lebanon. 4 The disease was characterized by (i) a broad range of age at onset (6 months -19 years), (ii) the distal predominance of lower limb paralyses, (iii) the slow progressive course and secondary involvement of proximal and trunk muscles, (iv) late diaphragmatic dysfunction. The disease gene has been mapped to chromosome 11q13, in the 10 cM interval defined by loci D11S1889 and D11S1321, which encompasses the IGHMBP2 gene, already accounting for early and severe spinal muscular atrophy (SMA) with distal predominance and diaphragmatic paralysis (SMARD1). 5, 6 However, sequence analysis of the IGHMBP2 gene failed to detect any mutation in our Chronic DSMA patients. 4 We have performed haplotype analysis at the Chronic DSMA locus in a series of 12 European families. Using a homozygosity mapping strategy, we mapped the Chronic DSMA locus to a short genetic interval (2.6 cM) and showed evidence of a founder effect in 8/12 families.
Patients and methods

Families
Inclusion criteria for Chronic DSMA were: (1) motor weakness predominating at the distal part of the limbs, (2) early and severe foot extensor muscle involvement with intrinsic foot muscle atrophy, (3) secondary hand muscle weakness, predominating at the wrist and finger extensor muscles with interosseous muscle atrophy, (4) trunk muscle weakness with marked hyperlordosis, (5) evidence of muscle denervation on neurophysiological assays and/or muscle biopsy, with normal sensory action potentials and normal motor and sensory nerve conduction velocity, and (6) absence of SMN1 gene deletion.
A total of 12 European families were studied and blood samples were collected from 15 patients and 35 relatives, with informed consent. In five families, at least one parent originated from Italia (families 1, 4, 9, 10 and 12). Parents of the other families originated from France except for family 2, originating from Portugal ( Figure 1 ).
Genotyping
Genomic DNA was extracted according to the standard procedures. Linkage studies were performed using nine contiguous microsatellite DNA markers, mapping to the 11q13 region and spanning a 10.3 cM interval (sex average distance) in the following order: cen -D11S1889 -D11S913 -D11S4113 -D11S4136 -D11S1314 -D11S1369 -DSM4 -D11S4184 -D11S916 -D11S1321 -tel. Most of the markers were obtained from the Genethon map and ordered from the genome-integrated map of the UCSC genome database. 7 Marker DSM4 was found in the computerized sequence of BAC AP002381, from the Human Genome Project database, in the vicinity of loci D11S1369 and D11S4184. Polymorphic markers at the DSM4 locus were amplified using the forward primer: CATCTATGGAAACAGAAGCAC and the reverse primer: CAAGATTCTGATATGTAAGGAG. Allele frequencies were obtained by screening a panel of 50 unrelated healthy European individuals. Informativity of markers varied from 71.5 to 77.8%. PCR amplification of microsatellite markers was carried out with 100 ng genomic DNA in a 25 ml total reaction volume containing: 0.2 U of Taq polymerase (Invitrogen Life Technology), 1 mM of the 5 0 -fluorescent labeled forward primer and 1 mM of the reverse primer, 200 mM dNTPs, and 1 Â reaction buffer (50 mM KCl, 20 mM Tris-HCl pH 8.4, 2 mM MgCl 2 ). Amplification was performed using the following conditions: 941C for 5 min, followed by 35 cycles at 941C for 30 s, 551C for 30 s, and 721C for 30 s, with a final 5 min extension at 721C. PCR products were diluted, denatured at 941C during 5 min, and loaded on the ABI prism 3100 Genescan analyzer (Applied Biosystems). For the data analyses, the Genescan Analysis and Genotyper softwares were used.
Sequence analysis
For the IGHMBP2 gene sequence analysis, all 15 exons were amplified from family 1, 2 and 3 probant's genomic DNA, using the intronic primers and PCR conditions reported by Grohmann et al 6 Fragments were sequenced using the Big Dye Terminator Cycle Sequencing Kit v2 on a 3100 automated sequencer (ABI Prism, Applied Biosystems, 
Statistical analyses
For linkage studies, pairwise linkage analyses were performed using the M-LINK and LINKMAP options of the 5.1 version of the LINKAGE program 5l. 8 We also compared the allele frequencies of mutant and control chromosomes at the D11S1369, DSM4 and D11S4184 loci. Significance of linkage disequilibrium was tested using the standard w 2 -test.
Results
Haplotype analyses in inbred families 1 -3 revealed that all affected siblings were homozygotes for a common haplotype defined by loci D11S1369, DSM4 and D11S4184 in the 11q13.3 region (Figure 1 ). Recombination events in affected individuals placed the disease locus proximal to marker D11S916 in families 1 and 2 and distal to marker D11S1314 in family 2. The maximum lod score value was obtained at the DSM4 locus (Z max ¼ 6.66 at recombination fraction y ¼ 0.00) ( Table 1 ). These data support the view that the disease locus is located in the 2.6 cM interval defined by loci D11S1314 and D11S916. IGHMBP2 sequence analysis in the probants of families 1, 2 and 3 revealed a small number of DNA variants. All these variants were detected in the parent's DNA and in the control population, suggesting polymorphisms (data not shown). These DNA polymorphisms were homozygous in family 3 probant but were heterozygous in the probants of families 1 and 2 (Het 1178G4A and Het 1284 þ 5G4A, respectively).
Comparison of mutant chromosomes in the 12 European families suggested a common ancestral mutant haplotype. Indeed, Figure 1 (Table 2 ). In particular, allele 2 at the D11S1369 locus displayed strong linkage disequilibrium with the Chronic DSMA allele (47% in mutant chromosomes vs 10% in control European chromosomes, Po0.001). The same figure was observed for allele 3 at the DSM4 locus (38% in mutant chromosomes vs 5% in control European chromosomes, Po0.001).
Discussion
Autosomal recessive Chronic DSMA is a rare clinical variant of SMA, characterized by progressive motor weakness and muscular atrophy, predominating in the distal part of the limbs. Familial and sporadic forms have been reported, but the clinical delineation of the syndrome has been described by Gardner-Medwin et al 9 We have recently reported a large family originating from Lebanon, with childhood and adult onset in the same pedigree. We mapped the disease gene to a 10.3 cM region on chromosome 11q13 in this family and showed that the same gene accounts for different clinical forms differing by their severity and age at the onset of the disease. 4 Here, studying a series of 12 additional patients with Chronic DSMA with severe foot and hand interosseous muscle atrophy, predominating to extensor muscles and marked hyperlordosis, we give support to the view that Chronic DSMA gene maps to chromosome 11q13.3 and that Chronic DSMA is probably a genetically homogeneous condition in patients of European ancestry. Using the homozygosity mapping strategy, we were able to narrow the Chronic DSMA region to a 2.6 cM interval, between loci D11S1314 and D11S916. The IGHMBP2 gene, which accounts for spinal muscular atrophy with respiratory distress (SMARD1), is situated in the genetic interval defined by loci D11S913 and D11S4113, according to the Genome database. This chromosomal region is located centromeric to the new refined Chronic DSMA region, suggesting the exclusion of this gene as the disease gene for Chronic DSMA. 4, 6 In addition, evidence of two heterozygous IGHMBP2 DNA polymorphisms in the consanguinous individuals (families 1 and 2) strongly supports the absence of linkage to this gene. Our study shows that 38% of Chronic DSMA chromosomes (8/21) derived from a single founder chromosome. Statistical analyses confirmed partial linkage disequilibrium between Chronic DSMA and loci D11S1369 and DSM4 in the European population. The size of the common ancestral haplotype indicates that Chronic DSMA is probably an ancient trait in the European population.
The Chronic DSMA region corresponds to a physical distance of 1 M base. Ten genes have been reported in this interval, in the Human Genome database. We analysed the electronical sequences of the putative proteins encoded by these genes and their predicted function (Table 3) . Aminoacid sequence alignments to the human and rodent databases failed to detect any homology to the known genes involved in motor neuron disorders. In addition, none of these genes displayed specific and/or marked neuronal expression. Recruitment of novel European families presenting Chronic DSMA and genetic analysis at the 11q13.3 locus will hopefully help narrowing the critical region and excluding some of these genes. Sequence analysis of the candidate sequences will eventually lead to the identification of the gene causing Chronic DSMA.
